Erratum to: Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis (JAMA Internal Medicine (2016) 176:12 (1834-1842) DOI: 10.1001/jamainternmed.2016.6875);Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis

JAMA Internal Medicine

Volumn 176, Issue 12, 2016, Pages 1834-1842

  Pedersen, Simon B ^a,b   Langsted, Anne ^a,b   Nordestgaard, Børge G ^a,b,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c FREDERIKSBERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMYLASE PANCREAS ISOENZYME; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; AMYLASE;

ACUTE PANCREATITIS; ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; GROUPS BY AGE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MIGRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; BLOOD; DENMARK; METABOLISM; MIDDLE AGED; MYOCARDIAL INFARCTION; PANCREAS; PANCREATITIS; RISK; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; AMYLASES; COHORT STUDIES; DENMARK; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; LIPASE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PANCREAS; PANCREATITIS; RISK; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES;

EID: 85011281186     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2024.0643     Document Type: Erratum

References (48)

1. Lankisch PG, Apte M, Banks PA. Acute pancreatitis. Lancet. 2015;386(9988):85-96.
2. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143(5):1179-87.e13
3. Fagenholz PJ, Castillo CF, Harris NS, Pelletier AJ, Camargo CA Jr. Increasing United States hospital admissions for acute pancreatitis, 1988-2003. Ann Epidemiol. 2007;17(7):491-497.
4. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144(6):1252-1261.
5. Toskes PP. Hyperlipidemic pancreatitis. Gastroenterol Clin North Am. 1990;19(4):783-791.
6. Fortson MR, Freedman SN,Webster PD III. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol. 1995;90(12):2134-2139.
7. Lloret Linares C, Pelletier AL, Czernichow S, et al. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas. 2008;37(1):13-2.
8. Sandhu S, Al-Sarraf A, Taraboanta C, Frohlich J, Francis GA. Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: A retrospective cohort study. Lipids Health Dis. 2011; 10:157.
9. Hegele RA, Ginsberg HN, Chapman MJ, et al; European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2 (8):655-666.
10. Scherer J, Singh VP, Pitchumoni CS, Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol. 2014;48(3):195-203.
11. Valdivielso P, Ramírez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med. 2014;25(8):689-694.
12. Tenner S, Baillie J, DeWitt J, Vege SS; American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis.AmJ Gastroenterol. 2013;108(9):1400-1415, 1416.
13. Berglund L, Brunzell JD, Goldberg AC, et al; Endocrine society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97 (9):2969-2989.
14. Catapano AL, Reiner Z, De Backer G, et al; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(1):3-46.
15. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
16. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943): 626-635.
17. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk ofmyocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299-308.
18. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation. 2008;118(10): 993-1001.
19. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation. 2008;118(20):2047-2056.
20. Steiner MJ, Skinner AC, Perrin EM. Fasting might not be necessary before lipid screening: A nationally representative cross-sectional study. Pediatrics. 2011;128(3):463-470.
21. Langsted A, Nordestgaard BG. Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study. Clin Chem. 2011;57(3):482-489.
22. Sidhu D, Naugler C. Fasting time and lipid levels in a community-based population: A cross-sectional study. Arch Intern Med. 2012;172(22):1707-1710.
23. Mora S. Nonfasting for Routine Lipid Testing: From Evidence to Action. JAMA Intern Med. 2016; 176(7):1005-1006.
24. Nordestgaard BG, Langsted A, Mora S, et al; European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cutpoints-A joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem. 2016;62(7):930-946.
25. Clarke R, ShipleyM, Lewington S, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol. 1999;150(4): 341-353.
26. Hutcheon JA, Chiolero A, Hanley JA. Random measurement error and regression dilution bias. BMJ. 2010;340:c2289.
27. KnuimanMW, Divitini ML, Buzas JS, Fitzgerald PE. Adjustment for regression dilution in epidemiological regression analyses. Ann Epidemiol. 1998;8(1):56-63.
28. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32-41.
29. Havel RJ. Pathogenesis, differentiation and management of hypertriglyceridemia. Adv Intern Med. 1969;15:117-154.
30. Saharia P, Margolis S, Zuidema GD, Cameron JL. Acute pancreatitis with hyperlipemia: studies with an isolated perfused canine pancreas. Surgery. 1977;82(1):60-67.
31. Ewald N, Hardt PD, Kloer HU. Severe hypertriglyceridemia and pancreatitis: presentation and management. Curr Opin Lipidol. 2009;20(6): 497-504.
32. Czakó L, Szabolcs A, Vajda A, et al. Hyperlipidemia induced by a cholesterol-rich diet aggravates necrotizing pancreatitis in rats. Eur J Pharmacol. 2007;572(1):74-81.
33. Varbo A, Benn M, Tybjærg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128 (12):1298-1309.
34. Brunzell JD, Deeb SS. Familial lipoprotein Lipase Deficiency, Apo C-II Defiency, and Hepatic Lipase Deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. TheMetabolic & Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001:2789-2816.
35. Nordstoga K, Sørby R, Olivecrona G, Smith AJ, Christophersen B. Pancreatitis in hyperlipemic mink (Mustela vison). Vet Pathol. 2012;49(3):557-561.
36. Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res. 2016;118(4):547-563.
37. Nordestgaard BG, Zilversmit DB. Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits. J Lipid Res. 1988; 29(11):1491-1500.
38. Preiss D, Tikkanen MJ,Welsh P, et al. Lipid-modifying therapies and risk of pancreatitis: ameta-analysis. JAMA. 2012;308(8):804-811.
39. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007;176(8):1113-1120.
40. Garg R, ChenW, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: A retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33(11):2349-2354.
41. Yang L, He Z, Tang X, Liu J. Type 2 diabetes mellitus and the risk of acute pancreatitis: ameta-analysis. Eur J Gastroenterol Hepatol. 2013; 25(2):225-231.
42. Lindkvist B, Appelros S, Regnér S, Manjer J. A prospective cohort study on risk of acute pancreatitis related to serum triglycerides, cholesterol and fasting glucose. Pancreatology. 2012;12(4):317-324.
43. MurphyMJ, Sheng X, MacDonald TM,Wei L. Hypertriglyceridemia and acute pancreatitis. JAMA Intern Med. 2013;173(2):162-164.
44. Christian JB, Arondekar B, Buysman EK, Jacobson TA, Snipes RG, Horwitz RI. Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia. Am J Med. 2014;127(1): 36-44.e1.
45. Steinberg WM, Nauck MA, Zinman B, et al; LEADER Trial investigators. LEADER 3-lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. Pancreas. 2014;43(8):1223-1231.
46. Matull WR, Pereira SP, O'Donohue JW. Biochemical markers of acute pancreatitis. J Clin Pathol. 2006;59(4):340-344.
47. Lippi G, Valentino M, Cervellin G. Laboratory diagnosis of acute pancreatitis: in search of the Holy Grail. Crit Rev Clin Lab Sci. 2012;49(1):18-31.
48. Floyd A, Pedersen L, Nielsen GL, Thorladcius-Ussing O, Sorensen HT. Secular trends in incidence and 30-day case fatality of acute pancreatitis in North Jutland County, Denmark: A register-based study from 1981-2000. Scand J Gastroenterol. 2002;37(12):1461-1465.